I-Mab to Release Q3 2024 Financial Results on November 14, 2024

IMAB 10.31.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur IMAB Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
  • 01.06.2025 - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference (In Person)

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]

ROCKVILLE, Md.,Oct. 31, 2024/PRNewswire/ --I-Mab(NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter endedSeptember 30, 2024, onThursday, November 14, 2024, pre-market Eastern Time.

(PRNewsfoto/I-Mab Biopharma)

The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives. Information about financial results, conference calls, webcasts, and other information is posted on the Company's website.

About I-Mab

I-Mab(NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.

I-Mabhas established operations inRockville, Maryland, andShort Hills, New Jersey. For more information, please visithttps://www.i-mabbiopharma.comand follow us onLinkedInandX.

I-Mab Investor & Media ContactsTyler EhlerSenior Director, Investor RelationsIR@imabbio.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-release-q3-2024-financial-results-on-november-14-2024-302292364.html

SOURCEI-Mab Biopharma

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com